Esophagitis associated with the use of alendronate

New England Journal of Medicine

Volumn 335, Issue 14, 1996, Pages 1016-1021

  De Groen, Piet C ^a   Lubbe, Dieter F ^a   Hirsch, Laurence J ^b   Daifotis, Anastasia ^b   Stephenson, Wendy ^b   Freedholm, Debra ^b   Pryor Tillotson, Suzanne ^b   Seleznick, Mitchel J ^c   Pinkas, Haim ^c   Wang, Kenneth K ^a  

^a MAYO CLINIC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CISAPRIDE; LANSOPRAZOLE; OMEPRAZOLE; SUCRALFATE;

AGED; ARTICLE; CASE REPORT; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS HEMORRHAGE; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALENDRONATE; DIPHOSPHONATES; ESOPHAGITIS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; ULCER;

EID: 0010496839     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199610033351403     Document Type: Article

References (17)

1. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
2. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996;81:961-7
3. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal ostcoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99: 144-52.
4. Maconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-90.
5. Lufkin EG, Argucta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-2.
6. Fosamax (alendronate sodium tablets). West Point, Pa.: Mcrck, 1995 (package insert).
7. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288-98.
8. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17:383-90.
9. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf 1996;14:158-70.
10. Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 1994;15:415-7.
11. Marvola M, Rajaniemi M, Marttila E, Vahervuo K, Sothmann A. Effect of dosage form and formulation factors on the adherence of drugs to the esophagus. J Pharm Sci 1983;72:1034-6.
12. Channer KS, Virjee JP. The effect of size and shape of tablets on their esophageal transit. J Clin Pharmacol 1986;26:141-6.
13. Hey H, Jorgensen F, Sorensen K, Hasselbalch H, Wambcrg T. Oesophageal transit of six commonly used tablets and capsules. BMJ 1982; 285:1717-9.
14. Liberman UA, Hirsch LJ. Esophagitis and alendronate. N Engl J Med 1996;335:1069-70.
15. Inman WHW. The United Kingdom. In: Inman WHW, ed. Monitoring for drug safety. Philadelphia: J.B. Lippincott, 1980:9-47.
16. Bozymski EM, Isaacs KL. Medications reported to cause esophageal damage. In: Yamada T, ed. Textbook of gastroenterology. 2nd ed. Vol. 1. Philadelphia: J.B. Lippincott, 1995:1283-301.
17. Fosamax (alendronate sodium tablets). West Point, Pa.: Merck, 1996 (package insert).